Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology, 4(11):44-50 (1993). |
Flach et al., Topical Prostaglandin E.sub.2 Effects on Normal Human Intraocular Pressure, Journal of Ocular Pharmacology, 4(1):13-18 (1988). |
Giuffre, The Effects of Prostaglandin F.sub.2.alpha. the Human Eye, Graefe's Archive Ophthalmology, 222:139-141 (1985). |
Ichikawa, et al., Molecular Aspects of the Structures and Functions of the Prostaglandin E Receptors, J. Lipid Mediators Cell Signaling 14:83-87 (1996). |
Kerstetter et al., Prostaglandin F.sub.2.alpha. -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow, American Journal of Ophthalmology, 105:30-34 (1988). |
Nakajima et al., Effects of Prostaglandin D.sub.2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, 229:411-413 (1991). |
Thierauch et al., Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, 12:1-5 (1994). |
Waterbury, et al., EP.sub.3, But Not EP.sub.2, FP, or TP Prostanoid-Receptor Stimulation May Reduce Intraocular Pressure, Investigative Ophthalmology and Visual Science, 31(12):2560-2567 (1990). |
Woodward et al., Intraocular Pressure Effects of Selective Prostanoid Receptor Agonists Involve Different Receptor Subtypes According to Radioligand Binding Studies, J. of Lipid Mediators, 6:545-553 (1993). |
Woodward et al., Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP.sub.2 Receptor, Journal of Ocular Pharmacology and Therapeutics, 11(3):447-454 (1995). |